Compare LCID & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | MLTX |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2020 | 2020 |
| Metric | LCID | MLTX |
|---|---|---|
| Price | $7.45 | $19.76 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $15.71 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 19.9M | 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,271,000.00 | N/A |
| Revenue This Year | $71.67 | N/A |
| Revenue Next Year | $89.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $5.95 |
| 52 Week High | $25.22 | $62.75 |
| Indicator | LCID | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 52.93 |
| Support Level | $5.59 | $15.89 |
| Resistance Level | $10.79 | $21.14 |
| Average True Range (ATR) | 0.90 | 0.91 |
| MACD | 0.13 | -0.07 |
| Stochastic Oscillator | 97.78 | 46.10 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design, which led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.